{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002027","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2025-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.700357+00:00","generated_at":"2026-05-23T20:59:12.530256+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux","bullets":["Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.","Peter J. Weiler appointed CFO effective May 1, 2025; base salary of $300,000 USD per annum, target annual bonus of 40% of base salary, and $2,000/month auto allowance.","Weiler previously served as President of Exzell Pharma, Inc., and held business development roles at Biosyent Inc. and Cipher Pharmaceuticals Inc.","If terminated without cause, Weiler receives 12-24 months base salary plus benefits; enhanced change-of-control severance of 24 months base salary.","Lemieux's departure not due to any disagreement with Edesa; transition is planned and orderly."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002027","json":"https://secwatch.observer/filing/0001171843-25-002027.json","markdown":"https://secwatch.observer/filing/0001171843-25-002027.md","text":"https://secwatch.observer/filing/0001171843-25-002027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/f8k_040325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T20:59:12.530256+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"088990ffe2","claim":"Peter J. Weiler was appointed as Chief Financial Officer at Edesa Biotech, Inc..","evidence_excerpt":"the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"9bcb2f2d00","claim":"Stephen Lemieux resigned as Chief Financial Officer at Edesa Biotech, Inc..","evidence_excerpt":"Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325002027/0001171843-25-002027-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}